Canaccord Genuity Reiterates a 'Buy/Top Pick' Rating on Orexigen Therapeutics (OREX); Buy Before 12/7 Ad Com
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Orexigen Therapeutics (NASDAQ: OREX), PT $14.
Canaccord analyst says, "We reiterate our rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We reiterate our rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
